Duopharma Biotech maintains robust revenue and profit growth momentum
Duopharma Biotech Berhad reported a revenue of RM931.69 million for the year ended 31 December 2025, up 14.5% compared to revenue of RM813.70 million in financial year 2024.
Providing Smarter Solutions
For a
Healthier Life
Our core competencies lie in the research and development, manufacturing, commercialisation and marketing of over 300 generic drugs. These include popular brands such as Omesec, Prelica, CHAMPS®, FLAVETTES®, PROVITON® and Uphamol, which are well-recognised and accepted by consumers globally. We have also diversified into the biosimilars space, with technology and commercialisation collaborations with valuable international partners.
Results in Numbers
How we're making a difference in the healthcare ecosystem
More than
1500
People
More than
400
Products
Outlook
“Innovation is not just about new ideas — it is about having the courage to challenge the norm, the humility to learn, and the purpose to make a difference. At Duopharma Biotech, we are shaping the future of healthcare with heart, science, and a deep sense of responsibility. Let’s lead with purpose and build a future we can all be proud of.”
Priya Darshini A/P Asokan
Chief Innovation Officer
Generics Explained.
Generic medicines are required to be the same as branded medicines in terms of dosage, safety, effectiveness, strength, stability and quality. Generic medicines therefore have the same effects, risks and benefits as their branded counterparts. Differences are mainly cosmetic, in the shape, size, colour and packaging, none of which affects how the medicines work. Generic medicines cost a fraction of branded ones, making it more beneficial to national healthcare systems that make medical treatment more accessible.
Read more about generic medicine programmes in the USA, UK, Singapore and Malaysia.
Duopharma Biotech contributes RM300,000 to support Program Sekolah Angkat MADANI
Duopharma Biotech Berhad has contributed approximately RM300,000 in support of the Program Sekolah Angkat MADANI in 2025. In the initiative, the Company is supporting four schools, namely Sekolah Kebangsaan Bukit Naga and Sekolah Kebangsaan Seksyen 24, both in Shah Alam, Sekolah Kebangsaan Batu Unjur in Klang and Sekolah Menengah Kebangsaan Dato’ Abu Bakar Baginda in Bangi.
OUR BUSINESS AREAS
Excellence in Services
We are leaders in providing consultancy services with a set of cutting-edge technologies and a team of experienced and renowned professionals. These are some options that you can hire.
Updates
Duopharma Biotech contributes RM300,000 to support Program Sekolah Angkat MADANI
Duopharma Biotech Berhad has contributed approximately RM300,000 in support of the Program Sekolah Angkat MADANI in 2025. In the initiative, the Company is supporting four schools, namely Sekolah Kebangsaan Bukit Naga and Sekolah Kebangsaan Seksyen 24, both in Shah Alam, Sekolah Kebangsaan Batu Unjur in Klang and Sekolah Menengah Kebangsaan Dato’ Abu Bakar Baginda in Bangi.
Duopharma Biotech achieves strong profitability in Q3 FY2025
Duopharma Biotech Berhad achieved another milestone in Halal pharmaceuticals recently, when it received Halal Certification from the Department of Islamic Development Malaysia (JAKIM) for a biosimilar product used in the treatment of anaemia associated with chronic renal failure in adult haemodialysis and predialysis patients and paediatric patients on haemodialysis.
Duopharma Biotech appoints Group Chief Executive Officer
Duopharma Biotech Berhad has appointed Encik Wan Amir-Jeffery Bin Wan Abdul Majid as Group Chief Executive Officer of Duopharma Biotech Berhad effective 1 October 2025. Prior to this appointment, Encik Wan Amir-Jeffery [52], was Duopharma Biotech’s Chief Executive Officer – Group Operations.
Duopharma Biotech sustains year-on-year profit growth in H1 FY2025
Duopharma Biotech Berhad achieved another milestone in Halal pharmaceuticals recently, when it received Halal Certification from the Department of Islamic Development Malaysia (JAKIM) for a biosimilar product used in the treatment of anaemia associated with chronic renal failure in adult haemodialysis and predialysis patients and paediatric patients on haemodialysis.
Duopharma Biotech Records New Milestone in Halal-Certified Treatments
Duopharma Biotech Berhad achieved another milestone in Halal pharmaceuticals recently, when it received Halal Certification from the Department of Islamic Development Malaysia (JAKIM) for a biosimilar product used in the treatment of anaemia associated with chronic renal failure in adult haemodialysis and predialysis patients and paediatric patients on haemodialysis.
Duopharma Biotech Maintains Focus on Domestic Market Leadership and International Growth
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Records 36.2% Revenue Growth and 67.8% Profit Improvement in Q1 FY2025
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Achieves Record Revenue With 15.5% Growth in 2024
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech records strong growth in Q3 FY2024
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.